Some people wind up centenarians
Injection of mice with schistosomula after electroporation with Sm - TSP-1 and Sm - TSP-2 dsRNAs resulted in 61% and 83% reductions in the numbers of parasites recovered from the mesenteric veins four weeks later when compared to dsRNA-treated controls
This is a serious problem for several reasons: Muscle loss slows your resting metabolic rate, making it harder to keep weight off after stopping the medication Reduced muscle mass increases the risk of falls, fractures, and loss of physical function particularly in older adults The skinny fat phenomenon normal BMI but high body fat percentage is a real outcome of poorly managed GLP-1 use The solution is not to avoid GLP-1 medications
Summary of GLP1 adoption trends in Europe GLP1 uptake in Europe remains far lower than US levels Consumer scepticism across Europe limits weightloss drug use despite rising awareness Public healthcare coverage constraints slow adoption compared with commercially driven US Even optimistic scenarios predict only modest calorieintake reductions across Europe Gradual destigmatisation suggests slow growth but limited longterm market disruption GLP-1 receptor agonists have seen far greater traction in the US than in Europe
Additional restrictions and eligibility conditions may apply
But because it must be taken daily on an empty stomach with minimal water, and because absorption varies significantly day to day, achieving consistent steady-state levels takes longer and is less predictable
.jpg)
